Evidence mapPaperPMID 40614331Full record

ArticleEuropean journal of public health2025

Basing healthcare decisions on value: patient-reported outcomes for patients diagnosed with breast cancer in a European cohort.

Ania Gorostiza, Jon Cacicedo, Itxaso Alayo, Andere Frias, Patricia Cobos Baena, Inés Gallego Camiña, Isabel Álvarez López, Marta Fernández Calleja, Alina Rigabert, Maria Victoria Alonso Martínez and 7 more

Abstract read
In one paragraph

Article in European journal of public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ania GorostizaBiosistemak Institute for Health Systems Research, B Accelerator Tower (BAT), Bilbao, Bizkaia, Spain.ORCID 0000-0002-9747-5816
Jon CacicedoDepartment of Radiation Oncology, Cruces University Hospital/Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.
Itxaso AlayoBiosistemak Institute for Health Systems Research, B Accelerator Tower (BAT), Bilbao, Bizkaia, Spain.
Andere FriasDepartment of Radiation Oncology, Cruces University Hospital/Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.
Patricia Cobos BaenaOsakidetza Basque Health Service, Ezkerraldea Enkarterri Cruces Integrated Health Organisation, Mammary Pathology Service, Barakaldo, Bizkaia, Spain.
Inés Gallego CamiñaInnovation and Quality Deputy Direction, Osakidetza Basque Health Service, Ezkerraldea Enkarterri Cruces Integrated Health Organisation, Barakaldo, Bizkaia, Spain.
Isabel Álvarez LópezOsakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Medical Oncology, Donostia, Gipuzkoa, Spain.
Marta Fernández CallejaOsakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Mammary Pathology Service, Begiristain Doktorea Pasealekua, Donostia, Gipuzkoa, Spain.
Alina RigabertFundación Andaluza Beturia para la Investigación en Salud (FABIS), Huelva, Spain.
Maria Victoria Alonso MartínezFundación Andaluza Beturia para la Investigación en Salud (FABIS), Huelva, Spain.
Carolina Varela RodríguezHospital Universitario 12 de Octubre, Madrid, Spain.
Valentina DanesiOutcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Andrea RoncadoriOutcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Mario CamponeInstitut de Cancérologie de l'Ouest Angers-Nantes, France.ORCID 0000-0002-5196-5908
Ane FullaondoBiosistemak Institute for Health Systems Research, B Accelerator Tower (BAT), Bilbao, Bizkaia, Spain.
Borja García-LorenzoBiosistemak Institute for Health Systems Research, B Accelerator Tower (BAT), Bilbao, Bizkaia, Spain.ORCID 0000-0002-6546-4186
VOICE Study Group

Funding

Biosistemak InstituteRoche Diagnostics SLUValue-Based Healthcare for Outcomes in Breast and Lung Cancer in Europe
6 · The paper itself

Abstract

Improvements in breast cancer survival rate have been achieved through a variety of multimodal therapeutic approaches, which play a key role in the patients' healthcare pathway and their Patient-Reported Outcomes (PROs) from a Value-Based Healthcare (VBHC) perspective. This paper analyses differences in PROs of patients diagnosed with breast cancer according to their healthcare pathway. A cohort of 690 patients diagnosed with breast cancer between 2018 and 2020 at six European sites was used. PROs were assessed at baseline and 6 months using the International Consortium for Health Outcome Measures standard set. Archetypes defined by patient characteristics and treatment trajectories served as the basis for comparison. Multivariate linear regression models were used to analyse differences in PROs across archetypes. Functional scores generally worsened over 6 months, particularly in physical functioning, whereas emotional functioning improved. Archetypes undergoing mastectomy, with or without reconstruction, showed significant decreases in body image perception and satisfaction with breasts. Pain, fatigue, and peripheral symptoms were prevalent in most archetypes, with those receiving chemotherapy reporting the greatest symptom burden. Patients with in situ carcinoma and patients undergoing conservative surgery plus radiotherapy showed minimal deterioration. The use of PROs in a real-world setting enables the identification of differences across patient archetypes based on their therapeutic pathways. This information provides valuable insights for refining patient-centred care guiding VBHC strategies in oncology, developing of personalized care solutions, and facilitating Shared-Decision Making.

Indexed as

Breast NeoplasmsPatient Reported Outcome MeasuresAdultAgedCohort StudiesEuropeFemaleHumansMiddle Aged

Identifiers

PMID40614331
PMCPMC12529264

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.